Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease.

Szczegóły
Abstrakt

Tytuł:: Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease.
Autorzy:: Hradsky O; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic. .
Kazeka D; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Copova I; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Lerchova T; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Mitrova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Pospisilova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Sulovcova M; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Zarubova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Bronsky J; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Źródło:: European journal of pediatrics [Eur J Pediatr] 2021 Sep; Vol. 180 (9), pp. 3001-3008. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Berlin : Springer Verlag
Original Publication: Berlin, New York, Springer-Verlag.
MeSH Terms:: Crohn Disease*/complications
Crohn Disease*/drug therapy
Tumor Necrosis Factor Inhibitors*
Child ; Humans ; Infliximab/adverse effects ; Retrospective Studies ; Risk Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha
References:: Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132(3):863–873; quiz 1165-1166. https://doi.org/10.1053/j.gastro.2006.12.003. (PMID: 10.1053/j.gastro.2006.12.00317324398)
Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y, Huang B, Bittle B, Marshall M, Lazar A (2012) Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 143(2):365–374 e362. https://doi.org/10.1053/j.gastro.2012.04.046. (PMID: 10.1053/j.gastro.2012.04.04622562021)
Jongsma M, Aardoom M, Cozijnsen M, van Pieterson M, de Meij T, Norbruis O, Groeneweg M, Wolters V, van Wering H, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, Rheenen P, van Wijk M, Teklenburg-Roord S, Escher J, Samsom J, Ridder L (2020) OP38 Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s disease: a multicentre randomised controlled trial. J Crohn's Colitis 14(Supplement_1):S039–S039. https://doi.org/10.1093/ecco-jcc/jjz203.037. (PMID: 10.1093/ecco-jcc/jjz203.037)
van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-Lopez VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM (2020) The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 15:171–194. https://doi.org/10.1093/ecco-jcc/jjaa161. (PMID: 10.1093/ecco-jcc/jjaa161)
Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R (2018) Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155(2):337–346 e310. https://doi.org/10.1053/j.gastro.2018.04.012. (PMID: 10.1053/j.gastro.2018.04.01229655835)
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ (2012) Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 107(9):1409–1422. https://doi.org/10.1038/ajg.2012.218. (PMID: 10.1038/ajg.2012.218228902233438468)
Freling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, Peyrin-Biroulet L (2015) Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol 110(8):1186–1196. https://doi.org/10.1038/ajg.2015.205. (PMID: 10.1038/ajg.2015.20526195181)
Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S (2016) Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 164(1):10–22. https://doi.org/10.7326/M15-0729. (PMID: 10.7326/M15-072926641955)
Sridhar S, Maltz RM, Boyle B, Kim SC (2018) Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm Bowel Dis 24:2086–2092. https://doi.org/10.1093/ibd/izy112. (PMID: 10.1093/ibd/izy11229718343)
Malkonen T, Wikstrom A, Heiskanen K, Merras-Salmio L, Mustonen H, Sipponen T, Kolho KL (2014) Skin reactions during anti-TNFalpha therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis 20(8):1309–1315. https://doi.org/10.1097/MIB.0000000000000088. (PMID: 10.1097/MIB.000000000000008824918318)
Courbette O, Aupiais C, Viala J, Hugot JP, Louveau B, Chatenoud L, Bourrat E, Martinez-Vinson C (2019) Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 69:189–193. https://doi.org/10.1097/MPG.0000000000002349. (PMID: 10.1097/MPG.000000000000234930921262)
Sherlock ME, Walters T, Tabbers MM, Frost K, Zachos M, Muise A, Pope E, Griffiths AM (2013) Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr 56(5):512–518. https://doi.org/10.1097/MPG.0b013e31828390ba. (PMID: 10.1097/MPG.0b013e31828390ba23274341)
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, Consortium RE (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208. (PMID: 10.1016/j.jbi.2019.1032083107866031078660)
Team RC (2020) R: A language and environment for statistical computing R Foundation for Statistical Computing.
Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63(4):567–577. https://doi.org/10.1136/gutjnl-2012-302853. (PMID: 10.1136/gutjnl-2012-30285323468464)
Nigam GB, Bhandare AP, Antoniou GA, Limdi JK (2020) Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol Publish Ahead of Print. https://doi.org/10.1097/MEG.0000000000001917.
Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, Grosber M, Pfab F, Schmidt-Weber CB, Mempel M, Hein R, Ring J, Cavani A, Eyerich K (2011) Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 365(3):231–238. https://doi.org/10.1056/NEJMoa1104200. (PMID: 10.1056/NEJMoa110420021774711)
Grant Information:: 00064203 Ministerstvo Zdravotnictví Ceské Republiky; NA Working Group of Pediatric Gastroenterology and Nutrition Associated with the Czech Pediatric Society of the Czech Medical Association of J. E. Purkyně
Contributed Indexing:: Keywords: Adalimumab; Eczema; Infliximab; Psoriasis; Skin complications
Substance Nomenclature:: 0 (Tumor Necrosis Factor Inhibitors)
0 (Tumor Necrosis Factor-alpha)
B72HH48FLU (Infliximab)
Entry Date(s):: Date Created: 20210420 Date Completed: 20210810 Latest Revision: 20210810
Update Code:: 20240105
DOI:: 10.1007/s00431-021-04077-0
PMID:: 33876264
: Czasopismo naukowe

Pełny tekst

Studies showing a substantial frequency of dermatologic complications in paediatric Crohn's disease (CD) patients on anti-tumour necrosis factor (TNF) therapy preferentially include patients treated with infliximab. We aimed to identify risk factors for the cumulative incidence of skin complications in a paediatric cohort receiving either adalimumab or infliximab and found an association between current skin complications and the patient's current clinical condition. This study retrospectively evaluated dermatologic complications in an inception cohort of 100 paediatric CD patients receiving the first anti-TNF (Motol PIBD cohort). Patient data were collected every 3 months. The lesions were classified as psoriatic, atopic dermatitis, or others. We used Cox regression to evaluate the association between predefined variables and the time to complication and a generalised linear mixed model to assess the association between the patient's current condition and the occurrence of complications. Among the 89 included children, 35 (39%) presented with dermatologic lesions. The only predictor associated with any complication was infliximab (versus adalimumab) therapy (hazard ratio [HR]: 2.07; 95% confidence interval [CI]: 1.03-4.17; p = 0.04). Infliximab therapy (HR: 5.5; 95%CI: 1.59-19.06; p = 0.01) and a family history of atopy (HR: 3.4; 95%CI 1.35-8.57, p = 0.002) were associated with early manifestation of atopic dermatitis. Lower C-reactive protein levels (odds ratio [OR], 0.947; 95% CI, - 0.898 to 0.998; p = 0.046) and infliximab (versus adalimumab) were associated with the occurrence of any dermatologic complications (OR, 5.93; 95% CI, 1.59-22.07; p = 0.008).Conclusion: The frequency of skin complications seems high in paediatric CD patients treated with anti-TNF and is even higher in those treated with infliximab. What is Known: •The dermatologic complications occur during treatment with anti-tumour necrosis factor. •The frequency of skin complications in paediatric patients with Crohn's disease is high. What is New: •Infliximab (vs. adalimumab) was identified as a strong risk factor for the cumulative incidence of skin complications. •Lower C-reactive protein levels were associated with the current occurrence of dermatologic complications.
(© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Informacja